Chimeric peptides for neuropeptide delivery through the blood-brain barrier
Patent 4801575 Issued on January 31, 1989. Estimated Expiration Date: 
July 30, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
July 30, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod and system for the controlled release of biologically active substances to a body fluid Cytotoxic compositions of transferrin coupled to vinca alkaloids Patent #: 4522750 InventorAssigneeApplicationNo. 06/891867 filed on 07/30/1986US Classes:514/4, With an additional active ingredient424/85.7, Alpha or leukocyte514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/3, Insulin or derivative530/302, Endorphin and Enkephalin; related peptides530/303, Insulin; related peptides530/311, Somatostatin (SRIF); related peptides530/351, Lymphokines, e.g., interferons, interlukins, etc.930/150, Oxytocin or vasopressin; related peptides930/160, Somatostatin; related peptides930/21, Containing D-amino acid930/24, Containing sulfur (See note 4)930/260, Containing Cys-Cys disulfide bridge between nonadjacent cysteine residues (See note 7)930/80Endorphin or Enkephalin; related peptidesExaminersPrimary: Hazel, BlondelAttorney, Agent or FirmInternational ClassesA61K 47/48 (20060101)C07K 7/00 (20060101) C07K 7/16 (20060101) C07K 1/00 (20060101) C07K 1/107 (20060101) C07K 14/435 (20060101) C07K 14/655 (20060101) C07K 14/675 (20060101) C07K 14/695 (20060101) C07K 14/62 (20060101) A61K 38/00 (20060101) AbstractChimeric peptides adapted for delivering neuropharmaceutical agents, such as neuropeptides into the brain by receptor-mediated transcytosis through the blood-brain barrier. The chimeric peptides include a peptide which by itself is capable of crossing the blood-brain barrier by transcytosis at a relatively high rate. The transportable peptide is conjugated to a hydrophilic neuropeptide which by itself is transportable only at a very low rate into the brain across the blood-brain barrier. The resulting chimeric peptide is transported into the brain at a much higher rate than the neuropeptide alone to thereby provide an effective means for introducing hydrophilic neuropeptides into the brain through the blood-brain barrier.Other References
|
| ||||||||||||||
